DMAC News and Press, DiaMedica Therapeutics Inc.

2024-07-11 14:48:34 ET Summary An interim futility analysis by the DSMB of DM199 for patients with AIS in the phase 2/3 ReMEDy2 trial is expected by Q1 of 2025. The global acute ischemic stroke therapeutics market size is expected to be worth $14 billion by 2032. Proof-of-conc...

Company to Host Preeclampsia Key Opinion Leader Event July 29, 2024 at 10 AM Eastern / 9 AM Central White Paper: The Potential of DM199 to Treat Preeclampsia DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel trea...

2024-07-10 16:28:06 ET More on DiaMedica Therapeutics Seeking Alpha’s Quant Rating on DiaMedica Therapeutics Historical earnings data for DiaMedica Therapeutics Financial information for DiaMedica Therapeutics Read the full article on Seeking Alpha ...

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic disease, today announced the closing of its previously announced $11.8 million private placement to accredited investors. The Company sold approximatel...

A look at the top 10 most actives in the United States Faraday Future Intelligent Electric Inc. (FFIE) rose 73.0% to $0.4585 on volume of 640,087,036 shares Ocean Power Technologies Inc. (OPTT) rose 34.9% to $0.1812 on volume of 396,326,565 shares NVIDIA Corporation (NVDA) rose 0.2% to $1...

2024-06-26 08:27:47 ET More on DiaMedica Therapeutics DiaMedica Therapeutics Inc. (DMAC) Q1 2024 Earnings Call Transcript Read the full article on Seeking Alpha For further details see: DiaMedica Therapeutics looks to raise $11.8M through private placement

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, today announced that it has entered into definitive agreements to sell its common shares in a private placement with accredited investors. Th...

Preeclampsia Program to be Initiated with a Phase 2 Investigator-sponsored Trial Beginning in Q4 2024 Key Proof-of-Concept Results Expected in the First Half of 2025 Management will Host a Conference Call Thursday, June 27, 2024 at 8:00 AM Eastern Time / 7:00 AM Central Time to Di...

2024-05-11 16:49:05 ET DiaMedica Therapeutics Inc. (DMAC) Q1 2024 Results Conference Call May 9, 2024 08:00 AM ET Company Participants Rick Pauls - President, CEO & Director Lorianne Masuoka - Chief Medical Officer Scott Kellen - CFO & Company Secretary ...

2024-05-08 16:49:29 ET More on DiaMedica Therapeutics DiaMedica Therapeutics Inc. (DMAC) Q4 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on DiaMedica Therapeutics Historical earnings data for DiaMedica Therapeutics Financial information f...